Fate Therapeutics FATE
NASDAQ FATE
$2.07 +0.01 (+0.49%)
At close: Oct 21, 2026 · 4:00 PM EDT

Fate Therapeutics (FATE) Preferred Stock Liabilities (2012 - 2013)

Updated

Fate Therapeutics (FATE) posted Preferred Stock Liabilities of $56.53 million for Q3 2013.

Analysis

Fate Therapeutics (FATE) Preferred Stock Liabilities (2012 - 2013) Analysis & Trends

  • In prior years, Fate Therapeutics' Preferred Stock Liabilities was $50.31 million in FY2011.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn -
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn -
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 Fate Therapeutics 248.02 Mn 94.22 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2013 56.53 Mn
Dec 31, 2012 56.53 Mn
API Access

Fate Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=FATE&period=max&api_key=YOUR_API_KEY